Navigation Links
Poniard Pharmaceuticals to Host Fourth Quarter and Year-End 2008 Financial Results Conference Call on March 12
Date:3/5/2009

SOUTH SAN FRANCISCO, Calif., March 5 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced that it will hold a conference call to discuss the Company's fourth quarter and year-end financial results and provide a corporate update, including ongoing development activities for picoplatin, the Company's lead product candidate.

Jerry McMahon, Ph.D., chairman and chief executive officer, Ronald A. Martell, president and chief operating officer, Greg Weaver, chief financial officer, and Robert De Jager, M.D., FACP, chief medical officer, will host the call beginning at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) on Thursday, March 12. A press release for the fourth quarter and year-ended December 31, 2008, will be released before market opening on March 12.

To participate in the live call by telephone, please dial 877-719-9791 from the U.S. or 719-325-4811 for international callers. In addition, the live conference call is being webcast and can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com. A replay of the webcast will be available on the Company's website for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. To date, clinical studies suggest that picoplatin has an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated w
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces New Efficacy and Safety Data from a Phase 2 Picoplatin Trial in Patients with Prostate Cancer
2. Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference
3. Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
4. Poniard Pharmaceuticals to Present Data from Phase 2 Clinical Trials of Picoplatin in Colorectal and Prostate Cancers
5. Poniard Pharmaceuticals Announces Commercial Supply Agreement for Picoplatin
6. Poniard Pharmaceuticals to Host Third Quarter 2008 Financial Results Conference Call on October 30
7. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
8. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
9. Poniard Pharmaceuticals to Present at the JMP Securities Healthcare Focus Conference
10. Poniard Pharmaceuticals Announces Upcoming Conference Participation
11. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 Earlier this year in a June ... the Adult Stem Cell Technology Center, LLC ( ASCTC ) ... property of adult tissue stem cells. His title “Asymmetric ... for the Future,” embodied the essence of his message to ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market to ... analyzed data about the vital drivers, restraints, trends, opportunities, strategies ... @ http://bit.ly/1yUxy0T , According to the report, the ... an impressive CAGR during near future. It expects this growth ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... - Covance Inc. has promoted Wendel Barr to the ... Anthony Cork to the position of president, early development, ... move supports the regional decision-making employed by its clients ... Tony have become corporate senior vice presidents and also ...
... Plan of New Jersey and announced an investment to ... Insurance Corp., Delta Dental Plan of Michigan, The Guardian ... Providers (the dental subsidiary of UnitedHealth Group). , ,These ... to enhance a platform that allows dentists to submit ...
... with innovation and excitement on its closing day, focusing ... next-generation systems designed to protect and defend the national ... email services. In addition to an array of new ... next "big thing" in a morning panel devoted to ...
Cached Biology Technology:Covance Appoints Co-Presidents for Early Development Services 2DEMO 2003 Closes with Focus on Collaboration and Communication 2DEMO 2003 Closes with Focus on Collaboration and Communication 3DEMO 2003 Closes with Focus on Collaboration and Communication 4
(Date:12/24/2014)... in December 2014, the 1U™ app has helped ... remember their usernames and passwords through replacing the antiquated system ... people who have struggled to remember usernames and passwords, ... on redefining identity, announced today that it is offering the ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... pioneer on synthetic biology who has engineered microbial "factories" ... drug and biofuel substitutes for gasoline, diesel and jet ... presented by the Heinz Family Foundation and carries with ... multiple titles, Keasling is the Associate Laboratory Director for ...
... research indicates marijuana-like compounds called endocannabinoids alter genes and ... placenta during pregnancy and may contribute to pregnancy complications ... edition of The Journal of Biological Chemistry ... lipid molecules produced by the body disrupts the movement ...
... A team of Australian researchers, led by University of Melbourne ... the risk of developing Autism Spectrum Disorder, ASD. Lead ... Engineering at the University of Melbourne said the test could ... "This test could assist in the early detection of ...
Cached Biology News:Jay Keasling wins Heinz Award 2Jay Keasling wins Heinz Award 3Jay Keasling wins Heinz Award 4Study implicates marijuana use in pregnancy problems 2Genetic test predicts risk for Autism 2